On Monday, Nuvation Bio Inc (NYSE: NUVB) opened higher 8.43% from the last session, before settling in for the closing price of $1.66. Price fluctuations for NUVB have ranged from $1.57 to $3.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 73.12% at the time writing. With a float of $226.82 million, this company’s outstanding shares have now reached $336.84 million.
Let’s look at the performance matrix of the company that is accounted for 220 employees. In terms of profitability, gross margin is 6.26%, operating margin of -2128.25%, and the pretax margin is -7213.76%.
Nuvation Bio Inc (NUVB) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nuvation Bio Inc is 33.03%, while institutional ownership is 45.76%. The most recent insider transaction that took place on Apr 01 ’25, was worth 166,985. In this transaction Director of this company bought 100,000 shares at a rate of $1.67, taking the stock ownership to the 200,000 shares. Before that another transaction happened on Nov 11 ’24, when Company’s CEO, ANHEART THERAPEUTICS LTD. sold 56,361 for $2.89, making the entire transaction worth $162,883. This insider now owns 3,866,228 shares in total.
Nuvation Bio Inc (NUVB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.20% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Check out the current performance indicators for Nuvation Bio Inc (NUVB). In the past quarter, the stock posted a quick ratio of 9.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.25, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE: NUVB) saw its 5-day average volume 3.74 million, a positive change from its year-to-date volume of 2.69 million. As of the previous 9 days, the stock’s Stochastic %D was 28.68%. Additionally, its Average True Range was 0.15.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 13.58%, which indicates a significant decrease from 52.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.94% in the past 14 days, which was lower than the 69.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0890, while its 200-day Moving Average is $2.6314. Nevertheless, the first resistance level for the watch stands at $1.9067 in the near term. At $2.0133, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1967. If the price goes on to break the first support level at $1.6167, it is likely to go to the next support level at $1.4333. Assuming the price breaks the second support level, the third support level stands at $1.3267.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
There are currently 338,679K shares outstanding in the company with a market cap of 609.62 million. Presently, the company’s annual sales total 7,870 K according to its annual income of -567,940 K. Last quarter, the company’s sales amounted to 5,710 K and its income totaled -49,450 K.
